{"venetoclax (VENCLEXTA Â®, AbbVie Inc. and Genentech Inc.)": {"Brand_Name": "VENCLEXTA",
  "Active_Ingredient": "venetoclax",
  "Company_name": "AbbVie Inc. and Genentech Inc."},
 "larotrectinib (VITRAKVI, Bayer Healthcare Pharmaceuticals, Inc.)": {"Brand_Name": "VITRAKVI",
  "Active_Ingredient": "larotrectinib",
  "Company_name": "Bayer Healthcare Pharmaceuticals, Inc."},
 "relugolix, (ORGOVYX, Myovant Sciences, Inc.)": {"Brand_Name": "ORGOVYX",
  "Active_Ingredient": "relugolix",
  "Company_name": "Myovant Sciences, Inc."},
 "cetuximab (Erbitux, ImClone LLC)": {"Brand_Name": "Erbitux",
  "Active_Ingredient": "cetuximab",
  "Company_name": "ImClone LLC"},
 "rituximab (Rituxan, Genentech, Inc.)": {"Brand_Name": "Rituxan",
  "Active_Ingredient": "rituximab",
  "Company_name": "Genentech, Inc."},
"nivolumab (Opdivo, Bristol Myers Squibb Company)": {"Brand_Name": "Opdivo",
  "Active_Ingredient": "nivolumab",
  "Company_name": "Bristol Myers Squibb Company"},
 "nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab" : {"Brand_Name": "Opdivo + Yervoy",
 "Active_Ingredient": "nivolumab + ipilimumab",
 "Company_name": "Bristol Myers Squibb Company"},
 "FoundationOne Liquid CDx test (Foundation Medicine, Inc.)" : {"Brand_Name": "",
 "Active_Ingredient": "",
 "Company_name": "Foundation Medicine, Inc."},
 "pembrolizumab (Keytruda, Merck)": {"Brand_Name": "Keytruda",
  "Active_Ingredient": "pembrolizumab",
  "Company_name": "Merck"},
 "pembrolizumab (KEYTRUDA, Merck)": {"Brand_Name": "KEYTRUDA",
  "Active_Ingredient": "pembrolizumab",
  "Company_name": "Merck"},
 "atezolizumab (Tecentriq) and paclitaxel": {"Brand_Name": "Tecentriq",
  "Active_Ingredient": "atezolizumab",
  "Company_name": ""},
 "Merck Sharp & Dohme Corp": {"Brand_Name": "KEYTRUDA",
  "Active_Ingredient": "pembrolizumab",
  "Company_name": "Merck Sharp & Dohme Corp."},
 "asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz Pharmaceuticals)": {"Brand_Name": "Rylaze",
  "Active_Ingredient": "asparaginase erwinia chrysanthemi (recombinant)-rywn",
  "Company_name": "Jazz Pharmaceuticals"},
 "capecitabine tablets (Xeloda, Genentech, Inc.)": {"Brand_Name": "Xeloda",
  "Active_Ingredient": "capecitabine tablets",
  "Company_name": "Genentech, Inc."},
 "niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.)": {"Brand_Name": "Akeega",
  "Active_Ingredient": "niraparib and abiraterone acetate",
  "Company_name": "Janssen Biotech, Inc."},
 "enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck)": {"Brand_Name": "Padcev, Keytruda",
  "Active_Ingredient": "enfortumab vedotin-ejfv in combination with pembrolizumab",
  "Company_name": "Astellas Pharma, Merck"},
 "bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.)": {"Brand_Name": "TECENTRIQ and AVASTIN",
  "Active_Ingredient": "bevacizumab",
  "Company_name": "Genentech Inc."},
 "nivolumab and ipilimumab (OPDIVO and YERVOY, Bristol-Myers Squibb Co.)": {"Brand_Name": "OPDIVO and YERVOY",
  "Active_Ingredient": "nivolumab and ipilimumab",
  "Company_name": "Bristol-Myers Squibb Co."},
  "(TUKYSA, Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine" : {"Brand_Name": "TUKYSA",
  "Active_Ingredient": "trastuzumab and capecitabine",
  "Company_name": "Seattle Genetics, Inc."},
  "ipilimumab (YERVOY, Bristol-Myers Squibb Company Inc.)" : {"Brand_Name": "YERVOY",
  "Active_Ingredient": "nivolumab and ipilimumab",
  "Company_name": "Bristol-Myers Squibb Company Inc."
  },
  "sirolimus protein-bound particles for injectable suspension" : {"Brand_Name": "Fyarro",
  "Active_Ingredient": "sirolimus protein-bound particles for injectable suspension (albumin-bound)",
  "Company_name": "Aadi Bioscience, Inc."
  },
  "asparaginase erwinia chrysanthemi" : {"Brand_Name": "Rylaze",
  "Active_Ingredient": "asparaginase erwinia chrysanthemi (recombinant)-rywn)",
  "Company_name": "Jazz Pharmaceuticals, Inc."
  },
  "safety labeling changes for fluorouracil injection products":{"Brand_Name": "",
  "Active_Ingredient": "fluorouracil",
  "Company_name": "FDA Office of Generic Drugs and the Oncology Center of Excellence (OCE)"
  },
  "the following for the first-line treatment of patients with advanced or metastatic esophageal squamous" : {"Brand_Name": "",
  "Active_Ingredient": "first-line treatment of patients with advanced or metastatic esophageal squamous (ESCC)",
  "Company_name": "FDA Office"
  },
  "the liquid biopsy next-generation sequencing-based FoundationOne Liquid CDx test" : {"Brand_Name": "",
  "Active_Ingredient": "liquid biopsy next-generation sequencing-based FoundationOne Liquid CDx test",
  "Company_name": "Foundation Medicine, Inc."
  },
  "fluorouracil injection" : {"Brand_Name": "fluorouracil",
  "Active_Ingredient": "",
  "Company_name": ""
  }
  }
